MOVE Quote, Financials, Valuation and Earnings

Ainos has a net margin of -14402% compared to Movano's net margin of -3093.98%. Movano's return on equity of -- beat Ainos's return on equity of -82.37%.

Movano has a consensus price target of $30.00, signalling upside risk potential of 4445.46%. On the other hand Ainos has an analysts' consensus of -- which suggests that it could fall by --. Given that Movano has higher upside potential than Ainos, analysts believe Movano is more attractive than Ainos.

Movano has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Ainos has a beta of 2.202, suggesting its more volatile than the S&P 500 by 120.24%.

Movano has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ainos offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Movano pays -- of its earnings as a dividend. Ainos pays out -- of its earnings as a dividend.

Movano quarterly revenues are $50K, which are smaller than Ainos quarterly revenues of $106.2K. Movano's net income of -$7.2M is lower than Ainos's net income of -$3.3M. Notably, Movano's price-to-earnings ratio is -- while Ainos's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Movano is -- versus 56.59x for Ainos. Usually stocks with elevated PS ratios are considered overvalued.

Intelligent Bio Solutions has a net margin of -14402% compared to Movano's net margin of -348.97%. Movano's return on equity of -- beat Intelligent Bio Solutions's return on equity of -149.7%.

Movano has a consensus price target of $30.00, signalling upside risk potential of 4445.46%. On the other hand Intelligent Bio Solutions has an analysts' consensus of -- which suggests that it could grow by 528.27%. Given that Movano has higher upside potential than Intelligent Bio Solutions, analysts believe Movano is more attractive than Intelligent Bio Solutions.

Movano has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Intelligent Bio Solutions has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Movano has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intelligent Bio Solutions offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Movano pays -- of its earnings as a dividend. Intelligent Bio Solutions pays out -- of its earnings as a dividend.

Movano quarterly revenues are $50K, which are smaller than Intelligent Bio Solutions quarterly revenues of $728.9K. Movano's net income of -$7.2M is lower than Intelligent Bio Solutions's net income of -$2.5M. Notably, Movano's price-to-earnings ratio is -- while Intelligent Bio Solutions's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Movano is -- versus 2.86x for Intelligent Bio Solutions. Usually stocks with elevated PS ratios are considered overvalued.

Standard BioTools has a net margin of -14402% compared to Movano's net margin of -63.81%. Movano's return on equity of -- beat Standard BioTools's return on equity of -26.52%.

Movano has a consensus price target of $30.00, signalling upside risk potential of 4445.46%. On the other hand Standard BioTools has an analysts' consensus of $2.38 which suggests that it could grow by 126.19%. Given that Movano has higher upside potential than Standard BioTools, analysts believe Movano is more attractive than Standard BioTools.

Movano has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Standard BioTools has a beta of 1.500, suggesting its more volatile than the S&P 500 by 50.042%.

Movano has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Standard BioTools offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Movano pays -- of its earnings as a dividend. Standard BioTools pays out -- of its earnings as a dividend.

Movano quarterly revenues are $50K, which are smaller than Standard BioTools quarterly revenues of $40.8M. Movano's net income of -$7.2M is higher than Standard BioTools's net income of -$26M. Notably, Movano's price-to-earnings ratio is -- while Standard BioTools's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Movano is -- versus 2.32x for Standard BioTools. Usually stocks with elevated PS ratios are considered overvalued.

LENSAR has a net margin of -14402% compared to Movano's net margin of -193.13%. Movano's return on equity of -- beat LENSAR's return on equity of -464.33%.

Movano has a consensus price target of $30.00, signalling upside risk potential of 4445.46%. On the other hand LENSAR has an analysts' consensus of $15.00 which suggests that it could grow by 20%. Given that Movano has higher upside potential than LENSAR, analysts believe Movano is more attractive than LENSAR.

Movano has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison LENSAR has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Movano has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LENSAR offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Movano pays -- of its earnings as a dividend. LENSAR pays out -- of its earnings as a dividend.

Movano quarterly revenues are $50K, which are smaller than LENSAR quarterly revenues of $14.2M. Movano's net income of -$7.2M is higher than LENSAR's net income of -$27.3M. Notably, Movano's price-to-earnings ratio is -- while LENSAR's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Movano is -- versus 2.54x for LENSAR. Usually stocks with elevated PS ratios are considered overvalued.